

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following testing methods is best suited for detecting PTEN deficiency?**
 - a. FISH (fluorescence in situ hybridization)
 - b. IHC (immunohistochemistry)**
 - c. Next-generation sequencing
 - d. All of the above methods are equally effective
- 2. In the Phase II BRCAaway study of abiraterone/prednisone, olaparib or the combination for metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM mutations, what was the median overall survival for patients receiving the combination therapy?**
 - a. 28 months
 - b. 37 months
 - c. 68 months**
 - d. None of the above
- 3. Activation of AKT in prostate cancer is most commonly associated with which genetic alteration?**
 - a. TP53 mutation
 - b. PTEN deficiency**
 - c. BRCA2 mutation
 - d. CHK2 mutation
- 4. Which of the following descriptions best characterizes the design of the IDEate-Prostate01 trial?**
 - a. A Phase I/II study evaluating the addition of ifinatamab deruxtecan (I-DXd) to docetaxel for previously treated mCRPC
 - b. A Phase II dose-optimization study evaluating 2 dose levels of I-DXd for previously treated mCRPC
 - c. A Phase III study evaluating I-DXd versus docetaxel for previously treated mCRPC**
- 5. Which of the following drug types best reflects the mechanism of action of opevesostat?**
 - a. Androgen receptor pathway inhibitor
 - b. CYP11A1 inhibitor**
 - c. AKT inhibitor
 - d. EZH2 inhibitor